CYP3A4 is a cytochrome P450 monooxygenase that catalyzes oxidative metabolism of endogenous substrates and xenobiotics through insertion of molecular oxygen into carbon-hydrogen bonds, with electrons provided by NADPH via cytochrome P450 reductase 1. Functionally, CYP3A4 metabolizes approximately 30-50% of marketed drugs, making it the most abundant hepatic and intestinal phase I enzyme 23. Beyond drug metabolism, CYP3A4 catalyzes hydroxylation of estrogens (2-hydroxy and 16α-hydroxylated estrone and estradiol), oxidative deactivation of testosterone to 2β- and 6β-hydroxytestosterones, formation of oxysterols from cholesterol, and hydroxylation of polyunsaturated fatty acids 456. CYP3A4 also metabolizes retinoids, catalyzing the rate-limiting conversion of all-trans-retinol to all-trans-retinal, and inactivates calcitriol (active vitamin D) 78. Genetic polymorphisms cause significant inter-individual variability in enzymatic activity, leading to altered drug efficacy or toxicity requiring personalized dosage adjustments 2. Drug-drug interactions involving CYP3A4 inhibitors (macrolide antibiotics, antiretrovirals) or inducers (rifampin, phenytoin) are clinically important, potentially causing unfavorable or fatal outcomes 3. Rare loss-of-function variants have been documented 9. Clock gene expression (DBP) regulates CYP3A4 activity in response to benzodiazepine exposure 10.